Glukosalina Iii

Glukosalina III is an intravenous solution for injection that contains sodium chloride and glucose. The product is supplied as a sterile liquid preparation, marketed in the European Union and available by prescription. It provides both electrolyte (sodium chloride) and carbohydrate (glucose) components in a single formulation, intended to support fluid balance and energy needs when administered intravenously in hospitals or emergency settings or urgent care environments.

Glukosalina III is indicated for clinical situations that require rapid restoration of fluid volume, electrolyte balance, or glucose levels. It is commonly used in hospital settings, including emergency departments, intensive care units, and perioperative care. - Fluid replacement in dehydration or blood loss. - Maintenance of electrolyte balance during surgery or critical illness. - Treatment of hypoglycemia when oral glucose is not feasible. - Provision of caloric support in patients unable to receive enteral nutrition. - Dilution and administration of other intravenous medications as a compatible carrier. - Correction of electrolyte disturbances such as hyponatremia during acute care.

The safety profile of Glukosalina III reflects the typical reactions associated with intravenous electrolyte and glucose solutions. Common: - Mild irritation at the injection site. - Transient increase in blood glucose levels. - Slight electrolyte shifts causing temporary nausea. - Mild headache or dizziness during infusion. - Temporary feeling of warmth or flushing at the infusion site. - Occasional mild metallic taste if solution contacts oral mucosa. Serious: - Hypernatremia from excessive sodium administration. - Severe hypoglycemia if glucose is insufficiently balanced. - Allergic reactions such as rash, itching, or anaphylaxis. - Fluid overload leading to pulmonary edema in patients with compromised cardiac function. - Severe electrolyte imbalance causing cardiac arrhythmias. - Risk of infection if aseptic technique is not maintained during administration.

When using Glukosalina III, clinicians should observe specific precautions to minimize risks and ensure appropriate therapy. - Verify patient’s electrolyte status and serum sodium levels before infusion. - Adjust infusion rate in patients with cardiac, renal, or hepatic impairment. - Monitor blood glucose regularly during and after administration. - Use aseptic technique and inspect the solution for particulate matter or discoloration. - Avoid rapid large-volume infusions unless clinically indicated. - Assess for any history of hypersensitivity to sodium chloride or glucose solutions. - Document volume and concentration administered in the patient record.

Glukosalina III may interact with other intravenous therapies or medications that affect fluid, electrolyte, or glucose balance. Avoid: - Co-administration with hypertonic saline solutions, which can cause excessive sodium load. - Simultaneous infusion of high-dose insulin without glucose supplementation, increasing risk of hypoglycemia. - Mixing with incompatible drugs that precipitate in the presence of chloride ions. - Concurrent infusion of potassium chloride solutions without proper monitoring can lead to dangerous potassium accumulation. Use with caution: - Concurrent use of diuretics, requiring close monitoring of electrolyte status. - Administration alongside vasopressors, as fluid shifts may alter hemodynamic response. - Use with other carbohydrate-containing solutions, to avoid hyperglycemia. - When combined with blood products, monitor for changes in serum sodium and glucose to prevent imbalances.